

# Jacek Gronwald

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4140145/publications.pdf>

Version: 2024-02-01

301  
papers

22,897  
citations

15880

67  
h-index

11946

139  
g-index

313  
all docs

313  
docs citations

313  
times ranked

23317  
citing authors

#	ARTICLE	IF	CITATIONS
1	Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. <i>American Journal of Human Genetics</i> , 2003, 72, 1117-1130.	2.6	3,105
2	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	13.7	1,099
3	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	2.6	711
4	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. <i>Journal of the National Cancer Institute</i> , 2011, 103, 250-263.	3.0	596
5	Pathologic Complete Response Rates in Young Women With <i>BRCA1</i> -Positive Breast Cancers After Neoadjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 375-379.	0.8	500
6	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	9.4	493
7	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. <i>British Journal of Cancer</i> , 2008, 98, 1457-1466.	2.9	461
8	CHEK2 Is a Multiorgan Cancer Susceptibility Gene. <i>American Journal of Human Genetics</i> , 2004, 75, 1131-1135.	2.6	426
9	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	3.8	390
10	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
11	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 362-370.	9.4	326
12	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. <i>Nature Genetics</i> , 2010, 42, 874-879.	9.4	321
13	A locus on 19p13 modifies risk of breast cancer in <i>BRCA1</i> mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <i>Nature Genetics</i> , 2010, 42, 885-892.	9.4	309
14	International variation in rates of uptake of preventive options in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>International Journal of Cancer</i> , 2008, 122, 2017-2022.	2.3	306
15	Response to neoadjuvant therapy with cisplatin in <i>BRCA1</i> -positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 359-363.	1.1	299
16	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	9.4	289
17	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. <i>Nature Genetics</i> , 2009, 41, 996-1000.	9.4	276
18	Contribution of Germline Mutations in the <i>RAD51B</i> , <i>RAD51C</i> , and <i>RAD51D</i> Genes to Ovarian Cancer in the Population. <i>Journal of Clinical Oncology</i> , 2015, 33, 2901-2907.	0.8	266

#	ARTICLE	IF	CITATIONS
19	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	9.4	265
20	Dose-Response Association of CD8 <sup>+</sup> Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, e173290.	3.4	260
21	Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. <i>International Journal of Cancer</i> , 2006, 118, 2281-2284.	2.3	246
22	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	1.5	244
23	Common variants at 19p13 are associated with susceptibility to ovarian cancer. <i>Nature Genetics</i> , 2010, 42, 880-884.	9.4	235
24	Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 401-405.	1.1	224
25	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	1.1	224
26	Founder Mutations in the BRCA1 Gene in Polish Families with Breast-Ovarian Cancer. <i>American Journal of Human Genetics</i> , 2000, 66, 1963-1968.	2.6	222
27	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	9.4	221
28	RAD51 135G <sup>A</sup> T <sup>C</sup> Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. <i>American Journal of Human Genetics</i> , 2007, 81, 1186-1200.	2.6	217
29	Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3747-3752.	0.8	207
30	Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1361-1367.	3.0	179
31	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2012, 14, R110.	2.2	179
32	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	1.5	174
33	CA125 and Ovarian Cancer: A Comprehensive Review. <i>Cancers</i> , 2020, 12, 3730.	1.7	174
34	A high proportion of founder BRCA1 mutations in Polish breast cancer families. <i>International Journal of Cancer</i> , 2004, 110, 683-686.	2.3	170
35	Germline RECQL mutations are associated with breast cancer susceptibility. <i>Nature Genetics</i> , 2015, 47, 643-646.	9.4	168
36	Predictors of Contralateral Prophylactic Mastectomy in Women With a BRCA1 or BRCA2 Mutation: The Hereditary Breast Cancer Clinical Study Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 1093-1097.	0.8	161

#	ARTICLE	IF	CITATIONS
37	Bilateral Oophorectomy and Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	160
38	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	7.7	157
39	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2011, 20, 3289-3303.	1.4	152
40	Epigenetic analysis leads to identification of <i>HNF1B</i> as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013, 4, 1628.	5.8	144
41	Clinical outcomes in women with breast cancer and a <i>PALB2</i> mutation: a prospective cohort analysis. <i>Lancet Oncology</i> , The, 2015, 16, 638-644.	5.1	137
42	Response to neo-adjuvant chemotherapy in women with <i>BRCA1</i> -positive breast cancers. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 289-296.	1.1	136
43	Breast cancer risk variants at 6q25 display different phenotype associations and regulate <i>ESR1</i> , <i>RMND1</i> and <i>CCDC170</i> . <i>Nature Genetics</i> , 2016, 48, 374-386.	9.4	125
44	Breast and ovarian cancer risks to carriers of the <i>BRCA1</i> 5382insC and 185delAG and <i>BRCA2</i> 6174delT mutations: a combined analysis of 22 population based studies. <i>Journal of Medical Genetics</i> , 2005, 42, 602-603.	1.5	121
45	Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among <i>BRCA1</i> Mutation Carriers. <i>JAMA Oncology</i> , 2018, 4, 1059.	3.4	121
46	Incidence of colorectal cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: results from a follow-up study. <i>British Journal of Cancer</i> , 2014, 110, 530-534.	2.9	120
47	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	9.4	120
48	Ten-Year Survival in Patients With <i>BRCA1</i> -Negative and <i>BRCA1</i> -Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3191-3196.	0.8	112
49	A Range of Cancers Is Associated with the rs6983267 Marker on Chromosome 8. <i>Cancer Research</i> , 2008, 68, 9982-9986.	0.4	111
50	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630.	0.9	111
51	Breast cancer predisposing alleles in Poland. <i>Breast Cancer Research and Treatment</i> , 2005, 92, 19-24.	1.1	110
52	On the origin and diffusion of <i>BRCA1</i> c.5266dupC (5382insC) in European populations. <i>European Journal of Human Genetics</i> , 2011, 19, 300-306.	1.4	107
53	The incidence of endometrial cancer in women with <i>BRCA1</i> and <i>BRCA2</i> mutations: An international prospective cohort study. <i>Gynecologic Oncology</i> , 2013, 130, 127-131.	0.6	106
54	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in <i>RAD51C</i> and <i>RAD51D</i> . <i>Journal of the National Cancer Institute</i> , 2020, 112, 1242-1250.	3.0	106

#	ARTICLE	IF	CITATIONS
55	A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. <i>Journal of Medical Genetics</i> , 2006, 43, 863-866.	1.5	103
56	A deletion in CHEK2 of 5,395Åbp predisposes to breast cancer in Poland. <i>Breast Cancer Research and Treatment</i> , 2007, 102, 119-122.	1.1	102
57	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , 2013, 4, 1627.	5.8	98
58	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. <i>Breast Cancer Research</i> , 2014, 16, 3419.	2.2	97
59	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	5.8	93
60	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	5.8	90
61	Family History of Cancer and Cancer Risks in Women with BRCA1 or BRCA2 Mutations. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1874-1878.	3.0	89
62	An inherited NBN mutation is associated with poor prognosis prostate cancer. <i>British Journal of Cancer</i> , 2013, 108, 461-468.	2.9	89
63	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88
64	Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a caseâ€“control study. <i>Cancer Causes and Control</i> , 2008, 19, 1111-1119.	0.8	87
65	Hereditary ovarian cancer in Poland. <i>International Journal of Cancer</i> , 2003, 106, 942-945.	2.3	82
66	Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. <i>Breast Cancer Research and Treatment</i> , 2006, 95, 105-109.	1.1	82
67	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	5.8	78
68	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv315.	3.0	77
69	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 884-895.	0.9	71
70	A common variant of CDKN2A (p16) predisposes to breast cancer. <i>Journal of Medical Genetics</i> , 2005, 42, 763-765.	1.5	70
71	BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 201-211.	1.1	70
72	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 250-261.	1.3	70

#	ARTICLE	IF	CITATIONS
73	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2011, 20, 3304-3321.	1.4	68
74	Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 579-586.	1.1	68
75	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015, 24, 5955-5964.	1.4	68
76	Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2018, 150, 85-91.	0.6	65
77	Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?. <i>European Journal of Human Genetics</i> , 2007, 15, 237-241.	1.4	61
78	Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. <i>Journal of Medical Genetics</i> , 2010, 47, 99-102.	1.5	61
79	The RAD51 135 G>C Polymorphism Modifies Breast Cancer and Ovarian Cancer Risk in Polish BRCA1 Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 270-275.	1.1	59
80	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2014, 16, 3416.	2.2	57
81	Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. <i>International Journal of Cancer</i> , 2015, 137, 1136-1146.	2.3	56
82	Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 365-373.	1.1	55
83	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2011, 128, 2063-2074.	2.3	54
84	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	0.4	54
85	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. <i>Modern Pathology</i> , 2019, 32, 1834-1846.	2.9	54
86	Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention. <i>Clinical Genetics</i> , 2009, 75, 72-78.	1.0	53
87	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2019, 79, 505-517.	0.4	49
88	Risk of Ovarian Cancer and the NF- $\kappa$ B Pathway: Genetic Association with IL1A and TNFSF10. <i>Cancer Research</i> , 2014, 74, 852-861.	0.4	48
89	The 3020insC allele of NOD2 predisposes to early-onset breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 89, 91-93.	1.1	47
90	XPD Common Variants and their Association with Melanoma and Breast Cancer Risk. <i>Breast Cancer Research and Treatment</i> , 2006, 98, 209-215.	1.1	47

#	ARTICLE	IF	CITATIONS
91	Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. <i>Breast Cancer Research and Treatment</i> , 2007, 104, 299-308.	1.1	47
92	Common Variants at the 19p13.1 and <i>ZNF365</i> Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 645-657.	1.1	47
93	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	1.5	47
94	The VEGF_936_C>T 3'UTR polymorphism reduces <i>BRCA1</i> -associated breast cancer risk in Polish women. <i>Cancer Letters</i> , 2008, 262, 71-76.	3.2	46
95	Body mass index and breast cancer survival: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2017, 46, 1814-1822.	0.9	45
96	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , 2015, 10, e0128106.	1.1	44
97	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020, 26, 5411-5423.	3.2	43
98	<i>CDKN2A</i> common variants and their association with melanoma risk: a population-based study. <i>Cancer Research</i> , 2005, 65, 835-9.	0.4	43
99	Inheritance of deleterious mutations at both <i>BRCA1</i> and <i>BRCA2</i> in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016, 18, 112.	2.2	42
100	Constitutional <i>CHEK2</i> mutations are associated with a decreased risk of lung and laryngeal cancers. <i>Carcinogenesis</i> , 2008, 29, 762-765.	1.3	41
101	<i>BRCA1</i> -positive breast cancers in young women from Poland. <i>Breast Cancer Research and Treatment</i> , 2006, 99, 71-76.	1.1	40
102	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2011, 103, 105-116.	3.0	40
103	Pathology of breast cancer in women with constitutional <i>CHEK2</i> mutations. <i>Breast Cancer Research and Treatment</i> , 2005, 90, 187-189.	1.1	39
104	The spectrum of mutations predisposing to familial breast cancer in Poland. <i>International Journal of Cancer</i> , 2019, 145, 3311-3320.	2.3	39
105	The risk of breast cancer in women with a <i>BRCA1</i> mutation from North America and Poland. <i>International Journal of Cancer</i> , 2012, 131, 229-234.	2.3	38
106	Treatment of infertility does not increase the risk of ovarian cancer among women with a <i>BRCA1</i> or <i>BRCA2</i> mutation. <i>Fertility and Sterility</i> , 2016, 105, 781-785.	0.5	38
107	Cancer risks in first-degree relatives of <i>CHEK2</i> mutation carriers: effects of mutation type and cancer site in proband. <i>British Journal of Cancer</i> , 2009, 100, 1508-1512.	2.9	37
108	Evidence of a genetic link between endometriosis and ovarian cancer. <i>Fertility and Sterility</i> , 2016, 105, 35-43.e10.	0.5	37

#	ARTICLE	IF	CITATIONS
109	Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 421-427.	1.1	35
110	Recurrent mutations of <scp>BRCA1</scp> and <scp>BRCA2</scp> in Poland: an update. <i>Clinical Genetics</i> , 2015, 87, 288-292.	1.0	35
111	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. <i>British Journal of Cancer</i> , 2020, 123, 793-802.	2.9	35
112	A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer. <i>European Journal of Human Genetics</i> , 2003, 11, 955-958.	1.4	34
113	Germline MSH2 and MLH1 mutational spectrum including large rearrangements in HNPCC families from Poland (update study). <i>Clinical Genetics</i> , 2005, 69, 40-47.	1.0	34
114	Ovarian cancer susceptibility alleles and risk of ovarian cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Human Mutation</i> , 2012, 33, 690-702.	1.1	34
115	Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland. <i>Clinical Genetics</i> , 2015, 88, 366-370.	1.0	34
116	Early radiation exposures and BRCA1-associated breast cancer in young women from Poland. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 581-584.	1.1	33
117	BRCA1 mutations and prostate cancer in Poland. <i>European Journal of Cancer Prevention</i> , 2008, 17, 62-66.	0.6	33
118	BRCA1 mutations and colorectal cancer in Poland. <i>Familial Cancer</i> , 2010, 9, 541-544.	0.9	33
119	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. <i>Clinical Cancer Research</i> , 2015, 21, 5264-5276.	3.2	33
120	Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?. <i>Gynecologic Oncology</i> , 2017, 145, 346-351.	0.6	33
121	<i>BRCA1</i> promoter methylation in peripheral blood is associated with the risk of tripleâ€negative breast cancer. <i>International Journal of Cancer</i> , 2020, 146, 1293-1298.	2.3	33
122	Comparison of genomic abnormalities between BRCA1 and sporadic breast cancers studied by comparative genomic hybridization. <i>International Journal of Cancer</i> , 2005, 114, 230-236.	2.3	32
123	CHEK2-Positive Breast Cancers in Young Polish Women. <i>Clinical Cancer Research</i> , 2006, 12, 4832-4835.	3.2	32
124	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	0.6	32
125	Prevalence of the NOD2 3020insC mutation in aggregations of breast and lung cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 95, 141-145.	1.1	31
126	Direct-to-patient BRCA1 testing: the Twoj Styl experience. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 239-245.	1.1	31



#	ARTICLE	IF	CITATIONS
127	The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland. <i>Prostate</i> , 2013, 73, 542-548.	1.2	31
128	<i>AURKA</i>F31I Polymorphism and Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1416-1421.	1.1	30
129	Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population. <i>PLoS ONE</i> , 2018, 13, e0201065.	1.1	30
130	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1</i>/<i>2</i> Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	3.0	30
131	Variant alleles of the CYP1B1 gene are associated with colorectal cancer susceptibility. <i>BMC Cancer</i> , 2010, 10, 420.	1.1	28
132	CHEK2 mutations and HNPCC-related colorectal cancer. <i>International Journal of Cancer</i> , 2010, 126, 3005-3009.	2.3	28
133	The contribution of founder mutations in <i>BRCA1</i> to breast and ovarian cancer in Lithuania. <i>Clinical Genetics</i> , 2010, 78, 373-376.	1.0	28
134	Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. <i>Familial Cancer</i> , 2015, 14, 383-391.	0.9	28
135	Blood cadmium levels as a marker for early lung cancer detection. <i>Journal of Trace Elements in Medicine and Biology</i> , 2021, 64, 126682.	1.5	28
136	Vitamin D receptor variants and breast cancer risk in the Polish population. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 629-633.	1.1	27
137	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. <i>British Journal of Cancer</i> , 2012, 106, 2016-2024.	2.9	27
138	Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland. <i>International Journal of Cancer</i> , 2020, 147, 2793-2800.	2.3	27
139	Founder mutations in the BRCA1 gene in west Belarusian breast-ovarian cancer families. <i>Clinical Genetics</i> , 2001, 60, 470-471.	1.0	26
140	The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs. <i>Hereditary Cancer in Clinical Practice</i> , 2005, 3, 59.	0.6	26
141	BARD1 and breast cancer in Poland. <i>Breast Cancer Research and Treatment</i> , 2007, 107, 119-122.	1.1	26
142	Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study. <i>Cancer Causes and Control</i> , 2012, 23, 1065-1074.	0.8	26
143	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	2.2	26
144	Common germline polymorphisms associated with breast cancer-specific survival. <i>Breast Cancer Research</i> , 2015, 17, 58.	2.2	26

#	ARTICLE	IF	CITATIONS
145	Enhanced <i>GAB2</i> Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1495-1503.	1.9	26
146	Population-based targeted sequencing of 54 candidate genes identifies <i>PALB2</i> as a susceptibility gene for high-grade serous ovarian cancer. <i>Journal of Medical Genetics</i> , 2021, 58, 305-313.	1.5	26
147	Characterization of a familial RCC-associated t(2;3)(q33;q21) chromosome translocation. <i>Journal of Human Genetics</i> , 2001, 46, 685-693.	1.1	25
148	Phenocopies in breast cancer 1 (BRCA1) families: implications for genetic counselling. <i>Journal of Medical Genetics</i> , 2007, 44, e76-e76.	1.5	25
149	Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations. <i>Journal of Medical Genetics</i> , 2008, 46, 132-135.	1.5	25
150	Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 561-571.	1.1	25
151	Influence of the selenium level on overall survival in lung cancer. <i>Journal of Trace Elements in Medicine and Biology</i> , 2019, 56, 46-51.	1.5	25
152	BARD1 is a Low/Moderate Breast Cancer Risk Gene: Evidence Based on an Association Study of the Central European p.Q564X Recurrent Mutation. <i>Cancers</i> , 2019, 11, 740.	1.7	25
153	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). <i>Journal of Genetics and Genome Research</i> , 2015, 2, .	0.3	25
154	Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers. <i>Breast</i> , 2010, 19, 479-483.	0.9	24
155	A common nonsense mutation of the BLM gene and prostate cancer risk and survival. <i>Gene</i> , 2013, 532, 173-176.	1.0	24
156	Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 113-118.	1.1	24
157	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015, 36, 1341-1353.	1.3	24
158	The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study. <i>British Journal of Cancer</i> , 2016, 114, 1160-1164.	2.9	24
159	A Nonsynonymous Polymorphism in <i>IRS1</i> Modifies Risk of Developing Breast and Ovarian Cancers in <i>BRCA1</i> and Ovarian Cancer in <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1362-1370.	1.1	23
160	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. <i>Human Genetics</i> , 2014, 133, 481-497.	1.8	23
161	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. <i>British Journal of Cancer</i> , 2017, 116, 524-535.	2.9	23
162	Influence of the Levels of Arsenic, Cadmium, Mercury and Lead on Overall Survival in Lung Cancer. <i>Biomolecules</i> , 2021, 11, 1160.	1.8	23

#	ARTICLE	IF	CITATIONS
163	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	1.4	23
164	CDKN2A-positive breast cancers in young women from Poland. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 355-359.	1.1	22
165	Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 161-165.	1.1	22
166	The contribution of founder mutations in <i>BRCA1</i> to breast cancer in Belarus. <i>Clinical Genetics</i> , 2010, 78, 377-380.	1.0	22
167	Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. <i>Human Molecular Genetics</i> , 2011, 20, 2263-2272.	1.4	22
168	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , 2015, 39, 689-697.	0.6	22
169	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	1.1	22
170	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 307-320.	1.4	22
171	Translocation (X;1)(p11.2;q21) in a Papillary Renal Cell Carcinoma in a 14-Year-Old Girl. <i>Cancer Genetics and Cytogenetics</i> , 1998, 101, 159-161.	1.0	21
172	Detection of germline mutations in the BRCA1 gene by RNA-based sequencing. <i>Human Mutation</i> , 2001, 18, 149-156.	1.1	21
173	High Incidence of 4153delA BRCA1 Gene Mutations in Lithuanian Breast- and Breast-ovarian Cancer Families. <i>Breast Cancer Research and Treatment</i> , 2005, 94, 111-113.	1.1	21
174	Epistatic Relationship between the Cancer Susceptibility Genes CHEK2 and p27. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 572-576.	1.1	21
175	Identification of Patients at High Risk of Psychological Distress After BRCA1 Genetic Testing. <i>Genetic Testing and Molecular Biomarkers</i> , 2009, 13, 325-330.	0.3	21
176	Large-Scale Evaluation of Common Variation in Regulatory T Cell-Related Genes and Ovarian Cancer Outcome. <i>Cancer Immunology Research</i> , 2014, 2, 332-340.	1.6	21
177	PARS PLANA VITRECTOMY IN ADVANCED CASES OF VON HIPPEL-LINDAU EYE DISEASE. <i>Retina</i> , 2016, 36, 325-334.	1.0	21
178	Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium. <i>PLoS ONE</i> , 2011, 6, e20703.	1.1	21
179	Inherited NBN Mutations and Prostate Cancer Risk and Survival. <i>Cancer Research and Treatment</i> , 2019, 51, 1180-1187.	1.3	21
180	Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 987-992.	1.1	20

#	ARTICLE	IF	CITATIONS
181	Predictors of survival for breast cancer patients with a BRCA1 mutation. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 513-521.	1.1	20
182	The association between smoking and cancer incidence in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>International Journal of Cancer</i> , 2018, 142, 2263-2272.	2.3	20
183	Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status. <i>Journal of Medical Genetics</i> , 2005, 43, 424-428.	1.5	19
184	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756.	1.8	19
185	The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome. <i>Cancer Research and Treatment</i> , 2017, 49, 430-436.	1.3	19
186	Blood Copper Levels and the Occurrence of Colorectal Cancer in Poland. <i>Biomedicines</i> , 2021, 9, 1628.	1.4	19
187	Loss or reduction of Fhit expression in renal neoplasias: Correlation with histogenic class. <i>Human Pathology</i> , 1999, 30, 1276-1283.	1.1	18
188	CYP1B1 and predisposition to breast cancer in Poland. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 383-388.	1.1	18
189	A six-nucleotide deletion in the CASP8 promoter is not associated with a susceptibility to breast and prostate cancers in the Polish population. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 367-368.	1.1	18
190	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	0.6	18
191	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	1.1	18
192	Blood arsenic levels and the risk of familial breast cancer in Poland. <i>International Journal of Cancer</i> , 2020, 146, 2721-2727.	2.3	18
193	PALB2 mutations and prostate cancer risk and survival. <i>British Journal of Cancer</i> , 2021, 125, 569-575.	2.9	18
194	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. <i>Human Molecular Genetics</i> , 2016, 25, 3600-3612.	1.4	17
195	Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer. <i>Hereditary Cancer in Clinical Practice</i> , 2017, 15, 4.	0.6	17
196	Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction. <i>PLoS ONE</i> , 2016, 11, e0153844.	1.1	17
197	NOD2 variants and the risk of malignant melanoma. <i>European Journal of Cancer Prevention</i> , 2005, 14, 143-146.	0.6	16
198	Association of common WRAP 53 variant with ovarian cancer risk in the Polish population. <i>Molecular Biology Reports</i> , 2013, 40, 2145-2147.	1.0	16

#	ARTICLE	IF	CITATIONS
199	A personalised approach to prostate cancer screening based on genotyping of risk founder alleles. <i>British Journal of Cancer</i> , 2013, 108, 2601-2609.	2.9	16
200	Consortium analysis of gene and gene-gene interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 2023-2035.	1.5	16
201	The 3' untranslated region C>T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation. <i>Breast Cancer Research and Treatment</i> , 2007, 104, 67-74.	1.1	15
202	Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families. <i>Molecular Biology Reports</i> , 2013, 40, 6619-6623.	1.0	15
203	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. <i>Gynecologic Oncology</i> , 2015, 136, 542-548.	0.6	15
204	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. <i>British Journal of Cancer</i> , 2018, 118, 1123-1129.	2.9	15
205	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2018, 47, 450-459.	0.9	15
206	A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy. <i>Gynecologic Oncology</i> , 2019, 155, 270-274.	0.6	15
207	Serum selenium level and cancer risk: a nested case-control study. <i>Hereditary Cancer in Clinical Practice</i> , 2019, 17, 33.	0.6	15
208	Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8 <sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. <i>Journal of Pathology</i> , 2022, 256, 388-401.	2.1	15
209	Polymorphisms in MMP-1, MMP-2, MMP-7, MMP-13 and MT2A do not contribute to breast, lung and colon cancer risk in polish population. <i>Hereditary Cancer in Clinical Practice</i> , 2020, 18, 16.	0.6	14
210	Serum Selenium Level Predicts 10-Year Survival after Breast Cancer. <i>Nutrients</i> , 2021, 13, 953.	1.7	14
211	Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland. <i>European Journal of Cancer Prevention</i> , 2008, 17, 389-391.	0.6	13
212	Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 121-126.	1.1	13
213	Haplotype of the C61G>BRCA1</i> Mutation in Polish and Jewish Individuals. <i>Genetic Testing and Molecular Biomarkers</i> , 2009, 13, 465-469.	0.3	13
214	Variation in NF- $\kappa$ B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1421-1427.	1.1	13
215	The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 371-378.	1.1	13
216	Inherited variants in XRCC2 and the risk of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 657-663.	1.1	13

#	ARTICLE	IF	CITATIONS
217	Lung Cancer Occurrenceâ€™ Correlation with Serum Chromium Levels and Genotypes. <i>Biological Trace Element Research</i> , 2021, 199, 1228-1236.	1.9	13
218	Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer. <i>Cancers</i> , 2021, 13, 849.	1.7	13
219	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016, 7, 72381-72394.	0.8	13
220	A survey of preventive measures among BRCA1 mutation carriers from Poland. <i>Clinical Genetics</i> , 2007, 71, 153-157.	1.0	12
221	Survival from breast cancer in patients with CHEK2 mutations. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 397-403.	1.1	12
222	Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern Europe. <i>Familial Cancer</i> , 2015, 14, 145-149.	0.9	12
223	Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland. <i>Hereditary Cancer in Clinical Practice</i> , 2018, 16, 6.	0.6	12
224	Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 443-449.	1.1	12
225	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 217-228.	1.1	12
226	Survival from breast cancer in women with a BRCA2 mutation by treatment. <i>British Journal of Cancer</i> , 2021, 124, 1524-1532.	2.9	12
227	A protein truncating BRCA1 allele with a low penetrance of breast cancer. <i>Journal of Medical Genetics</i> , 2004, 41, e130-e130.	1.5	11
228	Integrin $\beta$ 3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk. <i>Journal of Medical Genetics</i> , 2007, 44, 408-411.	1.5	11
229	Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families. <i>Hereditary Cancer in Clinical Practice</i> , 2015, 13, 3.	0.6	11
230	Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. <i>International Journal of Epidemiology</i> , 2018, 47, 987-997.	0.9	11
231	Inherited Variants in BLM and the Risk and Clinical Characteristics of Breast Cancer. <i>Cancers</i> , 2019, 11, 1548.	1.7	11
232	Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland. <i>Cancers</i> , 2020, 12, 2321.	1.7	11
233	Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers. <i>Journal of Ovarian Research</i> , 2016, 9, 11.	1.3	10
234	Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 421-426.	1.1	10

#	ARTICLE	IF	CITATIONS
235	Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2020, 159, 820-826.	0.6	10
236	Prevalence of germline TP53 variants among early-onset breast cancer patients from Polish population. <i>Breast Cancer</i> , 2021, 28, 226-235.	1.3	10
237	Are Two-Centimeter Breast Cancers Large or Small?. <i>Current Oncology</i> , 2013, 20, 205-211.	0.9	9
238	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 446-454.	1.1	9
239	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. <i>PLoS ONE</i> , 2018, 13, e0197561.	1.1	9
240	Non-random transmission of mutant alleles to female offspring of BRCA1 carriers in Poland. <i>Journal of Medical Genetics</i> , 2003, 40, 719-720.	1.5	8
241	Combined iPLEX and TaqMan Assays to Screen for 45 Common Mutations in Lynch Syndrome and FAP Patients. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 82-90.	1.2	8
242	Serum Selenium Level and 10-Year Survival after Melanoma. <i>Biomedicines</i> , 2021, 9, 991.	1.4	8
243	BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update. <i>Hereditary Cancer in Clinical Practice</i> , 2021, 19, 13.	0.6	8
244	Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers. <i>Menopause</i> , 2020, 27, 1396-1402.	0.8	8
245	Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2022, 164, 514-521.	0.6	8
246	Population Screening for Cancer Family Syndromes in the West Pomeranian Region of Poland. <i>Hereditary Cancer in Clinical Practice</i> , 2006, 4, 56.	0.6	7
247	Hereditary breast and ovarian cancer. <i>Hereditary Cancer in Clinical Practice</i> , 2008, 6, 88.	0.6	7
248	The 4154delA mutation carriers in the BRCA1 gene share a common ancestry. <i>Familial Cancer</i> , 2009, 8, 1-4.	0.9	7
249	Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 769-774.	1.1	7
250	Genetic predisposition to male breast cancer in Poland. <i>BMC Cancer</i> , 2021, 21, 975.	1.1	7
251	Molecular Evidence for Derivation of Metastatic Cells from Minor Subclones of Primary Clear Renal Cell Carcinomas. <i>Cancer Detection and Prevention</i> , 1999, 23, 479-484.	2.1	7
252	Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations. <i>Familial Cancer</i> , 2009, 8, 473-478.	0.9	6

#	ARTICLE	IF	CITATIONS
253	The presence of prostate cancer at biopsy is predicted by a number of genetic variants. <i>International Journal of Cancer</i> , 2014, 134, 1139-1146.	2.3	6
254	BRCA1 founder mutations compared to ovarian cancer in Belarus. <i>Familial Cancer</i> , 2014, 13, 445-447.	0.9	6
255	Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 163-169.	1.1	6
256	Allelic modification of breast cancer risk in women with an NBN mutation. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 427-431.	1.1	6
257	Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers. <i>Cancers</i> , 2021, 13, 3345.	1.7	6
258	Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism. <i>BMC Cancer</i> , 2008, 8, 90.	1.1	5
259	Lynch syndrome mutations shared by the Baltic States and Poland. <i>Clinical Genetics</i> , 2014, 86, 190-193.	1.0	5
260	Large deletion causing von Hippel-Lindau disease and hereditary breast cancer syndrome. <i>Hereditary Cancer in Clinical Practice</i> , 2014, 12, 16.	0.6	5
261	The variant allele of the rs188140481 polymorphism confers a moderate increase in the risk of prostate cancer in Polish men. <i>European Journal of Cancer Prevention</i> , 2015, 24, 122-127.	0.6	5
262	Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?. <i>Menopause</i> , 2020, 27, 156-161.	0.8	5
263	Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 515-523.	1.1	5
264	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016, 7, 69097-69110.	0.8	5
265	An Assessment of GPX1 (rs1050450), DIO2 (rs225014) and SEPP1 (rs7579) Gene Polymorphisms in Women with Endometrial Cancer. <i>Genes</i> , 2022, 13, 188.	1.0	5
266	Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutations. <i>Journal of Applied Genetics</i> , 2004, 45, 255-63.	1.0	5
267	Risk of Second Primary Thyroid Cancer in Women with Breast Cancer. <i>Cancers</i> , 2022, 14, 957.	1.7	5
268	Spectrum and frequency of CHEK2 variants in breast cancer affected and general population in the Baltic states region, initial results and literature review. <i>European Journal of Medical Genetics</i> , 2022, 65, 104477.	0.7	5
269	A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet. <i>Hereditary Cancer in Clinical Practice</i> , 2006, 4, 58.	0.6	4
270	Review Selenium as a marker of cancer risk and of selection for control examinations in surveillance. <i>Wspolczesna Onkologia</i> , 2015, 1A, 60-61.	0.7	4



#	ARTICLE	IF	CITATIONS
271	Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 825-830.	1.2	4
272	Association of recurrent mutations in <i>BRCA1</i> , <i>BRCA2</i> , <i>RAD51C</i> , <i>PALB2</i> , and <i>CHEK2</i> with the risk of borderline ovarian tumor. <i>Hereditary Cancer in Clinical Practice</i> , 2022, 20, 11.	0.6	4
273	The impact of oophorectomy on survival from breast cancer in patients with <i>CHEK2</i> mutations. <i>British Journal of Cancer</i> , 2022, 127, 84-91.	2.9	4
274	Clinical characteristics of breast cancer in patients with an <i>NBS1</i> mutation. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 471-476.	1.1	3
275	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 420-424.	1.1	3
276	The impact of an expanded genetic testing program and selective oophorectomy on the incidence of ovarian cancer in West Pomerania. <i>Clinical Genetics</i> , 2017, 91, 322-327.	1.0	3
277	rs495139 in the <i>TYMS-ENOSF1</i> Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2473.	1.8	3
278	Evaluation of Microfluidics-FISH method in prenatal diagnosis. <i>Ginekologia Polska</i> , 2017, 88, 670-673.	0.3	3
279	Selenium as marker for cancer risk and prevention. <i>Polski Przegląd Chirurgiczny</i> , 2012, 84, 470-5.	0.2	3
280	Bilateral Oophorectomy and the Risk of Breast Cancer in <i>BRCA1</i> Mutation Carriers: A Reappraisal. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1351-1358.	1.1	3
281	Population Screening of <i>CHEK2</i> Mutations in Poland. <i>Hereditary Cancer in Clinical Practice</i> , 2006, 4, 57.	0.6	2
282	Male to female ratio among offspring of <i>BRCA1</i> mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2006, 97, 113-114.	1.1	2
283	Optimizing recruitment to a prostate cancer surveillance program among male <i>BRCA1</i> mutation carriers: invitation by mail or by telephone. <i>Hereditary Cancer in Clinical Practice</i> , 2013, 11, 17.	0.6	2
284	Weight Gain After Oophorectomy Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation. <i>Women's Health</i> , 2015, 11, 453-459.	0.7	2
285	Chromosomal abnormalities in renal cell neoplasms associated with acquired renal cystic disease. A series studied by comparative genomic hybridization and fluorescence in situ hybridization. , 1999, 187, 308.		2
286	An Assessment of Serum Selenium Concentration in Women with Endometrial Cancer. <i>Nutrients</i> , 2022, 14, 958.	1.7	2
287	Clinical Genetic Services for Familial Breast Cancer in Poland. <i>Disease Markers</i> , 1999, 15, 46-46.	0.6	1
288	Transmission of mutant alleles to female offspring of <i>BRCA1</i> carriers in Poland. <i>Journal of Medical Genetics</i> , 2005, 42, e40-e40.	1.5	1

#	ARTICLE	IF	CITATIONS
289	Low-risk Genes and Multi-organ Cancer Risk in the Polish Population. Hereditary Cancer in Clinical Practice, 2006, 4, 52.	0.6	1
290	First recurrent large genomic rearrangement in the BRCA1 gene found in Poland. Cancer Epidemiology, 2014, 38, 382-385.	0.8	1
291	Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy. Hereditary Cancer in Clinical Practice, 2019, 17, 10.	0.6	1
292	Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?. Cancers, 2021, 13, 5464.	1.7	1
293	Common Variant in ALDH2 Modifies the Risk of Breast Cancer Among Carriers of the p.K3326* Variant in BRCA2. JCO Precision Oncology, 2022, 6, e2100450.	1.5	1
294	Coverage of the Genetic Background of Breast Cancer in the Polish Population. Hereditary Cancer in Clinical Practice, 2006, 4, 25.	0.6	0
295	Selected aspects of genetic counselling for BRCA1 mutation carriers. Hereditary Cancer in Clinical Practice, 2007, 5, 3.	0.6	0
296	Low Blood-As Levels and Selected Genotypes Appears to Be Promising Biomarkers for Occurrence of Colorectal Cancer in Women. Biomedicines, 2021, 9, 1105.	1.4	0
297	Molecular Analyses in Diagnosis of High Genetic Predispositions to Malignancies.. Journal of Clinical Biochemistry and Nutrition, 2000, 28, 159-165.	0.6	0
298	Abstract POSTER-CTRL-1213: Whole exome and targeted resequencing, of population based ovarian cancer cases and controls, identifies susceptibility genes for ovarian cancer. , 2015, , .		0
299	Evaluation of the constructed device along with the software for digital archiving, sending the data, and supporting the diagnosis of cervical cancer.. Journal of Clinical Oncology, 2020, 38, e18017-e18017.	0.8	0
300	Clinical characteristics of hereditary ovarian cancer (HOC) in Poland. Ginekologia Polska, 2002, 73, 733-9.	0.3	0
301	Frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients in South-East Poland. Hereditary Cancer in Clinical Practice, 2022, 20, 12.	0.6	0